D. Andes, A. Pascual, and O. Marchetti, Antifungal therapeutic drug monitoring: established and emerging indications, Antimicrob. Agents Chemother, vol.53, pp.24-34, 2009.

S. Chhun, E. Rey, A. Tran, O. Lortholary, G. Pons et al., Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection, J. Chromatogr. B, vol.852, pp.223-228, 2007.

J. E. Conte, J. A. Jr, G. Golden, M. Krishna, E. Mciver et al., Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects, Antimicrob. Agents Chemother, vol.53, pp.703-707, 2009.

O. A. Cornely, J. Maertens, D. J. Winston, J. Perfect, A. J. Ullmann et al., Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia, N. Engl. J. Med, vol.356, pp.348-359, 2007.

R. Courtney, S. Pai, M. Laughlin, J. Lim, and V. Batra, Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults, Antimicrob. Agents Chemother, vol.47, pp.2788-2795, 2003.

R. Courtney, D. Wexler, E. Radwanski, J. Lim, and M. Laughlin, Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults, Br. J. Clin. Pharmacol, vol.57, pp.218-222, 2004.

M. Cuenca-estrella, M. C. Arendrup, E. Chryssanthou, E. Dannaoui, C. Lass-florl et al., Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST), Clin. Microbiol. Infect, vol.13, pp.1018-1022, 2007.

B. De-pauw, T. J. Walsh, J. P. Donnelly, D. A. Stevens, J. E. Edwards et al., Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group, Clin. Infect. Dis, vol.46, pp.1813-1821, 2008.

F. Ezzet, D. Wexler, R. Courtney, G. Krishna, J. Lim et al., Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations, Clin. Pharmacokinet, vol.44, pp.211-220, 2005.

, accession date. Posaconazole. FDA briefing document, 2009.

P. O. Gubbins, G. Krishna, A. Sansone-parsons, S. R. Penzak, L. Dong et al., Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients, Antimicrob. Agents Chemother, vol.50, pp.1993-1999, 2006.

G. Krishna, M. Abutarif, F. Xuan, M. Martinho, D. Angulo et al., Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome, Pharmacotherapy, vol.28, pp.1223-1232, 2008.

G. Krishna, M. Martinho, P. Chandrasekar, A. J. Ullmann, and H. Patino, Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease, Pharmacotherapy, vol.27, pp.1627-1636, 2007.

G. Krishna, A. Moton, L. Ma, M. M. Medlock, and J. Mcleod, Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers, Antimicrob. Agents Chemother, vol.53, pp.958-966, 2009.

O. Lortholary, E. Dannaoui, D. Raoux, D. Hoinard, A. Datry et al., vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European Committee on Antimicrobial Susceptibility Testing, vol.51, pp.3378-3380, 2007.

V. Nagappan and S. Deresinski, Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent, Clin. Infect. Dis, vol.45, pp.1610-1617, 2007.

A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille et al., Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes, Clin. Infect. Dis, vol.46, pp.201-211, 2008.

M. A. Pfaller, S. A. Messer, L. Boyken, C. Rice, S. Tendolkar et al., In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species, J. Clin. Microbiol, vol.46, pp.2568-2572, 2008.

. Lebeaux and . Al, ANTIMICROB. AGENTS CHEMOTHER

F. Sabatelli, R. Patel, P. A. Mann, C. A. Mendrick, C. C. Norris et al., In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts, Antimicrob. Agents Chemother, vol.50, pp.2009-2015, 2006.

G. R. Thompson, M. G. Iii, G. Rinaldi, S. A. Pennick, T. F. Dorsey et al., Posaconazole therapeutic drug monitoring: a reference laboratory experience, Antimicrob. Agents Chemother, vol.53, pp.2223-2224, 2009.

A. J. Ullmann, O. A. Cornely, A. Burchardt, R. Hachem, D. P. Kontoyiannis et al., Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection, Antimicrob. Agents Chemother, vol.50, pp.658-666, 2006.

A. J. Ullmann, J. H. Lipton, D. H. Vesole, P. Chandrasekar, A. Langston et al., Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease, N. Engl. J. Med, vol.356, pp.335-347, 2007.

J. A. Vazquez, D. J. Skiest, H. Tissot-dupont, J. L. Lennox, N. Boparai et al., Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection, HIV Clin. Trials, vol.8, pp.86-97, 2007.

T. J. Walsh, I. Raad, T. F. Patterson, P. Chandrasekar, G. R. Donowitz et al., Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial, Clin. Infect. Dis, vol.44, pp.2-12, 2007.

, THERAPEUTIC DRUG MONITORING OF POSACONAZOLE, vol.53, 2009.